Brought to you by 
Sepracor and UCB sign deal for Zyrtec
16 Jul 1999
Executive Summary
Using its successful strategy of developing and patenting improved chemical entities of profitable existing drugs, Sepracor has licensed to UCB Farchim SA exclusive rights (except in the US and Japan) to levocetirizine, an isomer of UCB's Zyrtec (racemic cetirizine), a popular antihistamine.
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Chiral Chemistry
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sepracor and UCB sign deal for Zyrtec
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice